Join Our Atrial Fibrillation Stroke Prevention Study

We invite you to participate in a groundbreaking clinical research study of an investigational medication for stroke prevention in individuals with atrial fibrillation (AFib). The study will test a once-monthly injection of a new study medication to see if it helps prevent strokes in individuals with atrial fibrillation who are not good candidates for oral blood thinners.

Qualified participants may receive investigational medication and study-related medical care at no cost, plus a chance to contribute to research that could help others like you. Compensation of $100 for each study visit completed may also be provided.

To qualify, individuals must meet the following criteria:

  • Age 65 or older.
  • Diagnosed with atrial fibrillation.
  • Not eligible for oral blood thinners.
  • Not a candidate for left atrial appendage closure (Watchman Device).

Additional criteria will be evaluated to determine eligibility.

What is the LILAC study?

This study (clinical trial) will examine whether the investigational drug abelacimab may help to prevent strokes in adults with AFib.

Why is this study important?

This study is testing the investigational drug abelacimab. Investigational means that abelacimab is not yet FDA-approved. It is a blood thinner, but it blocks a different part of the clotting pathway than the usual standard care blood thinners. Because of this unique action, the study drug might be able to prevent strokes without increasing the risk of serious bleeding.

What is a clinical research study?

A clinical research study tests the safety and effectiveness of investigational medication in human volunteers. Every new medication must be tested in this way before it can be used by the public. People who participate in these studies play a crucial role in helping doctors and researchers learn more about how to treat illnesses in the future.